XLOXilio Therapeutics, Inc.

$29M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$17M

Net Income

-$17M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$794,000

Balance Sheet

Total Assets

$158M

Total Liabilities

$35M

Stockholders' Equity

$124M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$131,000	+100.0%
Operating Income	-$17M	-$8M	-109.2%
Net Income	-$17M	-$8M	-105.3%

XLO Q1 2021 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena